Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
NCT06290765Phase 4Withdrawn
- Sponsor
- PharmaEssentia
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 4 trial of ropeginterferon alfa-2b in polycythemia vera (PV), sponsored by PharmaEssentia. Planned start Aug 2026; status: withdrawn.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT06290765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290765.